Conclusion
BRAIN METASTASES
Given the technical differences between the treatment platforms investigated in this single-institution study, linac-based SRS (Arm-B) did not lead to significantly lower rates of grade 2–3 RN versus the multi-source gamma-ray system (Arm-A) in a population of patients with limited brain metastases of limited volume. No significant difference in patients outcome was observed between both arms. Multicentric prospective randomized trials are needed to confirm this data further.